Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging. - Wikidata - awgldk - TriplyDB

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

http://www.wikidata.org/entity/Q37214791

about

11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis NIH workshop on clinical translation of molecular imaging probes and technology--meeting report.Differential white matter connectivity in early mild cognitive impairment according to CSF biomarkers Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications Imaging the role of amyloid in PD dementia and dementia with Lewy bodies.Prodromal dementia with Lewy bodies.The clinical safety, biodistribution and internal radiation dosimetry of flutemetamol (¹⁸F) injection in healthy Japanese adult volunteers.

P2860

Q24194742-21214B00-E22E-41F9-921F-8D65B8E4042C Q27004240-EE588FA1-C5D1-458D-B531-2BE14A949A67 Q30430958-5B825D20-BE7A-4F20-8319-9E34DBE8DDA6 Q35116529-D89A232A-76CA-4A2B-A27E-C387F7C24B14 Q36813196-9D6837DD-BBFC-46F6-9F0C-0DAEBB05C29C Q38228098-6D777B21-4885-4314-8B8C-35C6D13A55C4 Q38234457-BD3A6A66-AB58-4FF0-AE2F-252A7881B0AA Q40868156-677157DD-4C18-4CD3-9B77-CD6C0FF55AAE

P2860

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

http://www.wikidata.org/entity/Q37214791

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

@en

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

@nl

type

label

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

@en

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

@nl

prefLabel

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

@en

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

@nl

P1433

Q37214791-01DB4475-43A2-4ABF-94BD-1E17A5F5EB1E

P1476

Q37214791-E9769463-9347-42E8-9A8F-F17E6A3A19F6

P2093

Q37214791-04A89BAF-A0A9-4EAC-8B3A-7D2986DDA3A6

Q37214791-0FBF128E-FA5A-49EA-8E71-F74BBBE5563F

Q37214791-5860FD2F-CF85-4E2E-AAFB-439F141705E6

Q37214791-A4BA2465-3FA8-421F-9A38-EF4B801F855E

Q37214791-C27BB60D-3E9D-49C5-B5E3-FE00E44EBFF7

Q37214791-EF63258A-C2B8-43F4-879C-082305C00A84

P2860

Q37214791-0090D966-8A49-4F9C-BB5A-CDBA4B76D10E

Q37214791-0E7F3CAE-1312-4883-86E0-FA2BCB70C4B7

Q37214791-14F72E05-F3DF-45A6-A5ED-ABE046839C5A

Q37214791-2BF519A4-C212-4C5B-A725-D9FBDD670713

Q37214791-39B82560-A8E1-4720-B2F7-3A319103BDD4

Q37214791-441FB85F-04BA-4805-890A-11C29FB8AA6D

Q37214791-4897A741-4221-4F0A-A8CE-D1D88495BEDB

Q37214791-4B5A365A-A911-4DC1-968D-C945A6863DFB

Q37214791-5027548C-861D-4842-8307-13680ED5D90B

Q37214791-56B8DF3F-7013-403F-9693-D5118B5EE34E

P304

Q37214791-DB1908CF-E5B3-4DB6-A393-F77743DCB817

P31

Q37214791-94387B8B-390E-4BF6-B453-6776DF550EB6

P356

Q37214791-2C0B5459-267E-4DF4-87C2-6BFBA3DC2987

P407

Q37214791-907B754A-09C6-45E7-800B-7A0325331018

P433

Q37214791-AC92EAD5-00B1-4EA0-B3BB-048F03F02BA5

P478

Q37214791-22FEC02B-A2D0-4A35-9F4F-55A5AE865D14

P577

Q37214791-F51F19CD-C626-4B48-A2E4-4CFBB902F5BC

P5875

Q37214791-7BB2E471-42D2-4A4F-B4A1-1D6603536AC1

P698

Q37214791-622EAB93-5D83-453A-94CA-017C2F89A3C0

P921

Q37214791-316d3958-81f0-4990-be25-f0b1b1f1bccf

P932

Q37214791-FFE4C679-1235-4C6E-9A1B-A1522C31FAB2

P356

JNUMED.112.112599

P1433

The Journal of Nuclear Medicine

P1476

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

@en

P2093

Bruno Giordani

http://www.w3.org/2001/XMLSchema#string

James F Burke

http://www.w3.org/2001/XMLSchema#string

Kirk A Frey

http://www.w3.org/2001/XMLSchema#string

Robert A Koeppe

http://www.w3.org/2001/XMLSchema#string

Roger L Albin

http://www.w3.org/2001/XMLSchema#string

Sid Gilman

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Mild cognitive impairment: clinical characterization and outcome

Neuropathologic features of amnestic mild cognitive impairment

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

Stability of different subtypes of mild cognitive impairment among the elderly over a 2- to 3-year follow-up period.

Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study.

Amyloid imaging in mild cognitive impairment subtypes.

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

P304

887-893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.112.112599

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236189079

http://www.w3.org/2001/XMLSchema#string

P698

23572495

http://www.w3.org/2001/XMLSchema#string

P921

P932

3790329

http://www.w3.org/2001/XMLSchema#string